Cepharanthine (also known as 千金藤素) is a natural bisbenzylisoquinoline alkaloid extracted from the plant Stephania cepharantha Hayata, used traditionally in Chinese medicine. It is being investigated as a potential disease-modifying treatment for Parkinson's disease (PD) due to its multi-target neuroprotective properties.
- Phase: Preclinical / Early clinical
- Status: Ongoing
- Drug: Cepharanthine (千金藤素)
- Origin: Traditional Chinese Medicine compound
- Patient Population: Early to mid-stage Parkinson's disease patients
Cepharanthine exerts neuroprotective effects through multiple interconnected pathways:
- NF-κB Inhibition: Suppresses nuclear factor kappa-B signaling
- Cytokine Reduction: Decreases TNF-α, IL-1β, and IL-6 production
- Microglial Modulation: Reduces activated microglia in substantia nigra
- ROS Scavenging: Directly neutralizes reactive oxygen species
- NADPH Oxidase Inhibition: Reduces superoxide production
- Nrf2 Activation: Upregulates antioxidant response genes
- Caspase Inhibition: Blocks both intrinsic and extrinsic apoptotic pathways
- Bcl-2 Upregulation: Increases anti-apoptotic protein expression
- Mitochondrial Protection: Preserves mitochondrial membrane potential
- Aggregation Inhibition: Prevents formation of toxic alpha-synuclein oligomers
- Fibril Disassembly: May promote clearance of existing aggregates
- Autophagy Enhancement: Increases clearance of misfolded proteins
- Calcium Homeostasis: Modulates calcium channel activity
- Dopamine Protection: Preserves dopaminergic neurons
- Blood-brain Barrier Penetration: Evidence for CNS bioavailability
Clinical evaluation involves:
- Preclinical Studies: Cell and animal models of PD
- Phase 1 Trials: Safety and pharmacokinetics in healthy volunteers
- Phase 2 Trials: Efficacy signals in PD patients
- Biomarker Studies: Alpha-synuclein and inflammatory markers
Key findings from research:
- Preclinical Efficacy: Demonstrated neuroprotection in MPTP and 6-OHDA models
- Safety Profile: Generally well-tolerated in preclinical and early clinical studies
- Mechanistic Evidence: Multi-omics studies confirm anti-inflammatory effects
- Clinical Signals: Early trials show potential for motor symptom improvement
Cepharanthine represents a promising multi-target approach:
- Drug Repurposing: Leveraging traditional medicine for modern therapeutics
- Disease Modification: Potential to slow progression rather than just symptom management
- Combination Therapy: May work synergistically with dopaminergic medications
- Cost-effectiveness: Natural compound may offer affordable treatment options